/Investor DB

Irving Investors — Full Portfolio

8 tracked investments · listed companies and verified rows first

eGenesisegenesis.comFeb 2021

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGeorge M. Church(Director)

Co-investorsAlta PartnersARCH Venture Partnersb2ventureCatalio Capital Management, LPHBM Healthcare InvestmentsHBM Partners+12 more

Imagoimagobio.comin𝕏Nov 2020 · $80Macquired by Merck

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.

BiotechHealthtech

Co-investorsFrazier Life SciencesHighlight CapitalMRL Ventures FundXeraya CapitalAmgen VenturesBlackRock+5 more

LUMICKSlumicks.comin𝕏Apr 2021 · $93M

LUMICKS develops life science research tools that measure and apply forces around biological interactions to link structural and 'omics analysis to functional outcomes at the molecular and cellular level.

BiotechDeep TechHardwareMedical Devices

Andrea(Co-founder & Chief Scientific Officer)Gerrit(Co-founder & Director of Product Management and Marketing)Hugo(CEO)Edmee(Chief Financial Officer)Hannah(HR Director)

Co-investorsLauxera Capital PartnersSoftBank Vision FundEuropean Investment BankGilde HealthcarePura Vida InvestmentsT. Rowe Price

Metagenomimetagenomi.coin𝕏Jan 2022 · $175M

Metagenomi is a genetic medicines company developing therapies based on gene editing technologies to treat patients with serious diseases.

BiotechDeep TechHealthtechMedical DevicesBerkeley, US

Brian Thomas(Founder)inBrian Thomas Jillian Banfield(Founder)Jill Banfield(Founder)Jian Irish(President and CEO)

BoardAndrew Farquharson(Director)inJak Knowles(Director)

Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalFrazier Life SciencesHumboldt+5 more

Model Medicinesmodelmedicines.comin𝕏Nov 2021 · $4.1M

Model Medicines is an AI-powered biotechnology company that uses computation to discover and engineer small molecule drugs targeting disease-driving biological mechanisms.

AI & Machine LearningBiotechDeep TechDigital HealthLa Jolla, US

Daniel Haders(Founder)inDaniel Haders II, Ph.D(Founder, CEO)inSean Russell(Founder, Chief Operating Officer)inKip Quackenbush(Executive Officer, Director)inMarlon Evans(Executive Officer, Director)in

Co-investors8VCParticleNex Cubed

Snyk Securitysnyk.ioin𝕏Dec 2022

Snyk is a developer-focused security platform that identifies and fixes vulnerabilities in code, dependencies, containers, and cloud infrastructure using AI-powered analysis.

AI & Machine LearningCybersecurityDeveloper ToolsBoston, US

Guy Podjarny(Founder)inPeter McKay(Executive Officer, Director)inStephanie Dominy(Executive Officer)inAssaf Hefetz(Founder)Danny Grander(Founder)Peter McKay (CEO)(Founder)

Co-investors2050 CapitalAccelAlkeon InnovationAmity VenturesAmplify PartnersAtlassian Ventures+45 more

Verkadaverkada.comin𝕏Jun 2026

Verkada builds AI-powered physical security solutions that integrate video security, access control, alarms, intercoms, air quality sensors, and visitor management into a single cloud-based platform.

AI & Machine LearningCybersecurityEnterprise SoftwareIoTSan Mateo, US

Filip Kaliszan(Founder)inHans Robertson(Founder)inBenjamin Bercovitz(Founder)inJames Ren(Founder)inTim Wilcox(Executive Officer)inBen Bercovitz(Founder)

Co-investors515 VenturesAlkeon InnovationCapitalGDepth VenturesFelicis VenturesFifth Down Capital+22 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Shoreline Biosciences

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.